Clinical Trial Update: Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intravesical gemcitabine and docetaxel for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer; currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Michael A. O'Donnell | Conditions: Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Status: RECRUITING